Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66975-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- EPO antibody
- Antibody type
- Monoclonal
- Description
- EPO antibody (Cat. #66975-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human, mouse and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 1A11F3
- Vial size
- 20ul, 150ul
Submitted references Perfluorocarbon Nanoparticles Incorporating Ginkgolide B: Artificial O(2) Carriers with Antioxidant Activity and Antithrombotic Effect.
Molecular and Cellular Response of the Myocardium (H9C2 Cells) Towards Hypoxia and HIF-1α Inhibition.
The hypoxia-inducible factor-α prolyl hydroxylase inhibitor FG4592 ameliorates renal fibrosis by inducing the H3K9 demethylase JMJD1A.
TCF11 Has a Potent Tumor-Repressing Effect Than Its Prototypic Nrf1α by Definition of Both Similar Yet Different Regulatory Profiles, With a Striking Disparity From Nrf2.
Meng W, Ye H, Ma Z, Liu L, Zhang T, Han Q, Xiang Z, Xia Y, Ke Y, Guan X, Shi Q, Ataullakhanov FI, Panteleev M
ChemMedChem 2024 Jan 2;19(1):e202300312
ChemMedChem 2024 Jan 2;19(1):e202300312
Molecular and Cellular Response of the Myocardium (H9C2 Cells) Towards Hypoxia and HIF-1α Inhibition.
Osuru HP, Lavallee M, Thiele RH
Frontiers in cardiovascular medicine 2022;9:711421
Frontiers in cardiovascular medicine 2022;9:711421
The hypoxia-inducible factor-α prolyl hydroxylase inhibitor FG4592 ameliorates renal fibrosis by inducing the H3K9 demethylase JMJD1A.
Ike T, Doi S, Nakashima A, Sasaki K, Ishiuchi N, Asano T, Masaki T
American journal of physiology. Renal physiology 2022 Nov 1;323(5):F539-F552
American journal of physiology. Renal physiology 2022 Nov 1;323(5):F539-F552
TCF11 Has a Potent Tumor-Repressing Effect Than Its Prototypic Nrf1α by Definition of Both Similar Yet Different Regulatory Profiles, With a Striking Disparity From Nrf2.
Wang M, Ren Y, Hu S, Liu K, Qiu L, Zhang Y
Frontiers in oncology 2021;11:707032
Frontiers in oncology 2021;11:707032
No comments: Submit comment
No validations: Submit validation data